Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib tosylate in patients with progressive metastatic neuroendocrine tumors has completed; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrinoma
• Gastrointestinal Carcinoid Tumor
• Glucagonoma
• Insulinoma
• Islet Cell Carcinoma
• Neuroendocrine Tumor
• Pancreatic Polypeptide Tumor

Drugs mentioned

• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrinoma, Glucagonoma | Phase 2 | Status: COMPLETED | Results posted: 2014-11-17